+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Crohn's Disease Therapeutics Market by Therapy Class (Biologics, Immunosuppressants, Small Molecules), Route Of Administration (Intravenous, Oral, Subcutaneous), Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Crohn's Disease Therapeutics Market by Therapy Class (Biologics, Immunosuppressants, Small Molecules), Route Of Administration (Intravenous, Oral, Subcutaneous), Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Crohn's Disease Therapeutics Market by Therapy Class (Biologics, Immunosuppressants, Small Molecules), Route Of Administration (Intravenous, Oral, Subcutaneous), Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 196 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6014389
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Crohn's Disease Therapeutics Market is undergoing significant transformation, as advances in targeted treatment and digital innovation drive new models of care across healthcare systems. Stakeholders are recalibrating strategies to adapt to changing regulatory, economic, and supply chain dynamics while responding to evolving patient needs.

Market Snapshot: Crohn's Disease Therapeutics Market

The Crohn's Disease Therapeutics Market grew from USD 13.36 billion in 2024 to USD 14.13 billion in 2025. It is expected to continue growing at a CAGR of 5.62%, reaching USD 18.55 billion by 2030. Market expansion is fueled by ongoing research into biologics, small molecule therapies, and real-world evidence collection strategies, positioning the sector to address the challenges of clinical efficacy, agile supply chains, and improved patient outcomes for global healthcare leaders.

Scope & Segmentation

This comprehensive report analyzes the landscape of Crohn's disease therapeutics by segment, region, and market participant, offering decision-makers actionable intelligence on the following areas:

  • Therapy Class: Biologics (including integrin inhibitors such as vedolizumab, interleukin inhibitors like risankizumab and ustekinumab, and TNF inhibitors adalimumab, certolizumab, and infliximab), immunosuppressants (methotrexate and thiopurines like azathioprine, mercaptopurine), and small molecule treatments (JAK inhibitors such as tofacitinib and upadacitinib).
  • Route of Administration: Intravenous, oral, subcutaneous.
  • Distribution Channel: Hospital pharmacies, retail pharmacies, specialty clinics.
  • End User: Home care settings, hospitals, specialty clinics.
  • Regional Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including key markets such as United Kingdom, Germany, France, Italy, Saudi Arabia, South Africa), and Asia-Pacific (with emphasis on China, India, Japan, Australia, South Korea, and Southeast Asian countries).
  • Industry Participants: Analysis of major players including AbbVie Inc., Janssen Biotech, Takeda Pharmaceutical Company, F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck & Co., UCB S.A., Celltrion, Samsung Bioepis, and Sandoz International.

Key Takeaways for Decision-Makers

  • Deployment of integrin and interleukin inhibitors is creating new pathways for gut-specific treatment, reducing reliance on traditional systemic immunosuppression.
  • Adoption of digital health tools, such as remote monitoring and telemedicine, is improving adherence and expanding access outside major clinical centers.
  • Personalized medicine initiatives, including genetic and microbiome profiling, are driving development of tailored treatment algorithms, improving the efficiency of therapy selection.
  • Biopharmaceutical manufacturers are accelerating innovation pipelines through cross-sector collaborations, adaptive clinical trial designs, and modernization of manufacturing processes.
  • Market access strategies are evolving in response to regional disparities, including unique payer systems and health economic requirements, influencing commercial launch and post-launch service models.
  • Distribution channel and administration route choices influence both patient experience and overall adherence, highlighting the need for flexibility across care environments.

Scheduled US Tariff Impact on Therapeutic Supply Chains

Impending tariff changes in the United States for 2025 are expected to introduce additional pressure on global supply chains for Crohn’s disease therapeutics. These adjustments are poised to raise material and production costs, and may lengthen lead times for essential biologic components and packaging. As a result, companies are reassessing their procurement strategies and increasing investment in local manufacturing, while healthcare providers and payers must prepare to revisit reimbursement structures to maintain uninterrupted patient access. Scenario planning and robust collaboration between supply chain managers, manufacturers, and policy teams will be essential to mitigate risks associated with these tariff-induced challenges.

Methodology & Data Sources

The insights presented derive from a mix of primary interviews with clinical, regulatory, and commercial leaders, supported by quantitative reviews of regulatory filings and clinical trial data. A rigorous triangulation of expert perspectives, peer-reviewed literature, and real-world evidence ensures a robust analytic framework underlying the report’s conclusions.

Why This Report Matters

  • Enables senior leaders to benchmark therapeutic innovation and commercial models against evolving regulatory and payer dynamics.
  • Provides actionable intelligence for optimizing pipeline investments and responding to shifts in clinical practice and patient demands.
  • Delivers geographic and technology-specific analysis supporting strategic planning in diverse healthcare markets.

Conclusion

Crohn’s Disease Therapeutics Market stakeholders face a landscape shaped by innovation, cost, and regulatory complexity. With actionable insights into treatments, supply chains, and future growth drivers, this report supports leaders in making informed, forward-looking decisions.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Impact of gut microbiome-targeted fecal microbiota transplant pipelines on Crohn’s disease management outcomes in clinical practice
5.2. Development and clinical trial progress of oral small-molecule S1P receptor modulators for moderate to severe Crohn’s disease
5.3. Adoption challenges and payer coverage landscape for high-cost biologic therapies in pediatric Crohn’s disease populations
5.4. Emerging role of personalized therapeutic drug monitoring using remote digital health platforms for Crohn’s disease remission maintenance
5.5. Strategic partnerships driving development of dual targeting anti-integrin and anti-TNF combination therapies in Crohn’s disease
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Crohn's Disease Therapeutics Market, by Therapy Class
8.1. Introduction
8.2. Biologics
8.2.1. Integrin Inhibitors
8.2.1.1. Vedolizumab
8.2.2. Interleukin Inhibitors
8.2.2.1. Risankizumab
8.2.2.2. Ustekinumab
8.2.3. TNF Inhibitors
8.2.3.1. Adalimumab
8.2.3.2. Certolizumab
8.2.3.3. Infliximab
8.3. Immunosuppressants
8.3.1. Methotrexate
8.3.2. Thiopurines
8.3.2.1. Azathioprine
8.3.2.2. Mercaptopurine
8.4. Small Molecules
8.4.1. JAK Inhibitors
8.4.1.1. Tofacitinib
8.4.1.2. Upadacitinib
9. Crohn's Disease Therapeutics Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Crohn's Disease Therapeutics Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Retail Pharmacies
10.4. Specialty Clinics
11. Crohn's Disease Therapeutics Market, by End User
11.1. Introduction
11.2. Home Care Settings
11.3. Hospitals
11.4. Specialty Clinics
12. Americas Crohn's Disease Therapeutics Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Crohn's Disease Therapeutics Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Crohn's Disease Therapeutics Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AbbVie Inc.
15.3.2. Janssen Biotech, Inc.
15.3.3. Takeda Pharmaceutical Company Limited
15.3.4. F. Hoffmann-La Roche Ltd
15.3.5. Pfizer Inc.
15.3.6. Merck & Co., Inc.
15.3.7. UCB S.A.
15.3.8. Celltrion, Inc.
15.3.9. Samsung Bioepis Co., Ltd.
15.3.10. Sandoz International GmbH
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. CROHN'S DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. CROHN'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. CROHN'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. CROHN'S DISEASE THERAPEUTICS MARKET: RESEARCHAI
FIGURE 24. CROHN'S DISEASE THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 25. CROHN'S DISEASE THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 26. CROHN'S DISEASE THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CROHN'S DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY VEDOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY VEDOLIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TOFACITINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TOFACITINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY UPADACITINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY UPADACITINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 141. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 142. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 143. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 144. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 145. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 146. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 147. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 148. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 149. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 150. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 151. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 152. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 153. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2024 (USD MILLION)
TABLE 154. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2025-2030 (USD MILLION)
TABLE 155. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 156. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 157. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 158. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 159. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 160. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 161. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 162. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 163. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 166. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 167. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 168. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 169. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 170. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 171. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 172. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 173. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 174. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 175. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 176. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 177. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2024 (USD MILLION)
TABLE 178. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2025-2030 (USD MILLION)
TABLE 179. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 180. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 181. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 182. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 183. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 186. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 187. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 264. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 266. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 268. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 270. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 272. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 274. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2024 (USD MILLION)
TABLE 276. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2025-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 278. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2018-2024 (USD MILLION)
TABLE 280. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, 2025-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. UNITED KINGDOM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
TABLE 288. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025-2030 (USD MILLION)
TABLE 289. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 290. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 291. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 292. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 293. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2024 (USD MILLION)
TABLE 294. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2025-2030 (USD MILLION)
TABLE 295. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2024 (USD MILLION)
TABLE 296. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2025-2030 (USD MILLION)
TABLE 297. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2024 (USD MILLION)
TABLE 298. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2025-2030 (USD MILLION)
TABLE 299. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2024 (USD MILLION)
TABLE 300. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2025-2030 (USD MILLION)
TABLE 301. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 302. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZ

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Crohn's Disease Therapeutics market report include:
  • AbbVie Inc.
  • Janssen Biotech, Inc.
  • Takeda Pharmaceutical Company Limited
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Merck & Co., Inc.
  • UCB S.A.
  • Celltrion, Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 14.13 Billion
Forecasted Market Value ( USD ) by 2030 $ 18.55 Billion
Compound Annual Growth Rate5.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Crohn`s Disease (CD) Therapy - Global Strategic Business Report - Product Image

Crohn`s Disease (CD) Therapy - Global Strategic Business Report

  • Report
  • 142 Pages
  • Global
From
Inflammatory Bowel Disease Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 - Product Image

Inflammatory Bowel Disease Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

  • Report
  • 145 Pages
  • Global
From
Ulcerative Colitis - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Ulcerative Colitis - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Crohn's Disease Therapeutics Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034) - Product Image

Crohn's Disease Therapeutics Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034)

  • Report
  • 400 Pages
  • Global
From
Inflammatory Bowel Disease (IBD) Therapeutics - Global Strategic Business Report - Product Image

Inflammatory Bowel Disease (IBD) Therapeutics - Global Strategic Business Report

  • Report
  • 146 Pages
  • Global
From

About the Crohn Disease Drug Market

Crohn Disease is a chronic inflammatory disorder of the gastrointestinal tract, and is one of the most common immune disorders. Treatment for Crohn Disease typically involves a combination of medications, lifestyle changes, and in some cases, surgery. Common medications used to treat Crohn Disease include corticosteroids, immunomodulators, biologic therapies, and antibiotics. Corticosteroids are used to reduce inflammation, while immunomodulators are used to suppress the immune system. Biologic therapies are used to target specific proteins in the body that are involved in the inflammatory process, and antibiotics are used to treat bacterial infections. The Crohn Disease Drug market is a rapidly growing segment of the Immune Disorders Drugs market. It is driven by the increasing prevalence of Crohn Disease, as well as the development of new and innovative treatments. Companies in the market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Pfizer, and UCB. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.